Greg Jones

Greg Jones

Company: Pfizer

Job title: Principle Scientist, Team Leader

Seminars:

Live Panel Q&A – Ask the Speakers Your Burning Questions 3:15 pm

Read more

day: Day Two

Live Panel Q&A – Ask the Speakers Your Burning Questions 12:50 pm

Read more

day: Day Two

Multi-Omics Data Integration Reveals Emerging Targets for RAS Mutant Cancers 2:50 pm

Targeting KRAS has proven clinical value for G12C mutant tumors – can this be expanded by a new wave of target ID, with distinct activity in intrinsic or acquired resistant models to G12C inhibition? Utilizing a combination of KRASG12Ci Resistant cell line models, and in vivo CRISPR drop out screens, reveals new targets required for…Read more

day: Day Two

Panel Discussion: Revealing Signaling Vulnerabilities: Reviewing Emerging Targets for RAS Mutated Cancers 2:40 pm

As the landscape of approaches targeting RAS mutated cancers continues to grow, there are a whole host of investigational inhibitors focused on targeting the RAS signaling pathway and the high value targets which exist within. Now more than ever, it is critical to understand the regulatory mechanisms downstream and upstream of RAS and consider the…Read more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.